Last reviewed · How we verify
Unresectable or metastatic melanoma
Approved treatments
- OPDUALAG · BRISTOL MYERS SQUIBB
- Opdualag · Australian & New Zealand Children's Haematology/Oncology Group
Clinical guidelines
- FDA label — 1L
COTELLIC® is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with vemurafenib.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Unresectable or metastatic melanoma patent landscape — cliff calendar, originator estates, attackable patents
- Unresectable or metastatic melanoma treatment landscape brief
- Unresectable or metastatic melanoma treatment updates RSS
Frequently asked questions about Unresectable or metastatic melanoma
What drugs treat Unresectable or metastatic melanoma?
Tracked treatments include OPDUALAG, Opdualag.
What is the treatment for Unresectable or metastatic melanoma?
Standard treatment for Unresectable or metastatic melanoma includes OPDUALAG, Opdualag. See the treatment landscape page for first-line, second-line and salvage options.
What are the treatment guidelines for Unresectable or metastatic melanoma?
FDA label publishes guidelines for Unresectable or metastatic melanoma. 1 guideline references tracked.
Related
- Treatment landscape: Unresectable or metastatic melanoma patent cliff · Unresectable or metastatic melanoma CI report
- Treatment: OPDUALAG · BRISTOL MYERS SQUIBB
- Treatment: Opdualag · Australian & New Zealand Children's Haematology/Oncology Group
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing